（文章来源：证券日报） 证券日报网讯 12月12日，金城医药在互动平台回答投资者提问时表示，目前公司经营情况正常。公司 深耕"医药化工、合成生物学、女性健康科技、高端抗感染、新型烟草"领域，形成了以五大领域为战略 支撑的整体发展布局。公司凭借着稳定优质的产品质量，在行业内拥有较好的口碑，像AE活性酯、头 孢他啶活性酯、谷胱甘肽原料药等，此外公司抗生素注射剂、口服剂以及妇科口服、外用制剂等产品也 以优秀的品质在各自的治疗领域发挥着重要作用。2025年，公司多项产品完成国内国际注册，产品更加 丰富，竞争力进一步提升。公司将不断加大市场开拓力度，积极拓展新客户、新市场，持续推动公司发 展和经营业绩的提升。 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 6.88% from November 17 to November 21, underperforming compared to the Wind All A index (-5.13%) and the CSI 300 index (-3.77%) [3][8] - All sub-sectors within the industry reported losses, with raw materials (-8.6%), offline pharmacies (-8.58%), and other biological products (-7.99%) leading the decline [3][8] - Major companies in the IVD sector are increasingly investing in cancer early screening, with Abbott announcing a $21 billion acquisition of Exact Sciences and Roche entering a partnership with Freenome valued at over $200 million [3][12] - Flu activity is on the rise, with the percentage of flu-like illness cases reported in southern provinces reaching 6.7%, up from 5.5% the previous week, and higher than the same period in previous years [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector fell by 6.88%, underperforming the broader market indices [8] - All sub-sectors declined, with raw materials and offline pharmacies showing the largest drops [8] - Individual stock performances varied, with Hainan Haiyao increasing by 23.8% while Jindike fell by 25.5% [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu cases in both southern and northern provinces, surpassing levels from previous years [11] Industry News - GE HealthCare announced a $2.3 billion acquisition of Intelerad, indicating a focus on cloud and AI solutions in healthcare [12] - Significant acquisitions and partnerships in the cancer diagnostics space were noted, including Abbott's acquisition of Exact Sciences and Roche's collaboration with Freenome [12][15] Company Announcements - Various companies announced significant developments, including clinical trial approvals and new drug applications, reflecting ongoing innovation in the sector [15][16]

（编辑 任世碧） 证券日报网讯 11月18日晚间，金城医药发布公告称，公司之全资子公司山东金城生物药业有限公司于 近日收到欧洲药品质量管理局（EDQM）核准签发的谷胱甘肽原料药欧洲药典适用性证书（简称"CEP 证书"）。 ...

Group 1 - Shengxin Lithium Energy signed a framework agreement with Huayou Cobalt for the procurement of 221,400 tons of lithium salt products over five years [1] - Wehua New Materials' subsidiary plans to acquire 70% of He Yutai for 154 million yuan [1] - Xiamen Tungsten plans to invest 600 million yuan to establish a wholly-owned subsidiary for a project with an annual production capacity of 50,000 tons of high-performance battery materials [1][2] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 200-300 million USD for two VLCCs [3] - Hailianxun's stock will resume trading on November 19 after the end of the acquisition request period [5] - Yunnan Energy Investment obtained the development rights for a 25,000 kW wind power project [7] Group 3 - China Resources Double Crane's subsidiary received a drug registration certificate for Oxcarbazepine tablets [8] - Jincheng Pharmaceutical's subsidiary received a CEP certificate for glutathione raw materials [9] - Jinkong Electric plans to transfer 51% of Tongying Thermal Power to an affiliate for 266 million yuan [9] Group 4 - Clean Technology's subsidiary won a bid for a waste incineration power generation project in Thailand with a total investment of up to 4.27 million USD [12] - Tonglian Precision's shareholders set the transfer price for shares at 43.67 yuan each [13] - Hu Nong Commercial Bank's executives collectively purchased 259,100 shares of the company [13] Group 5 - Huatai Medical's subsidiary obtained a medical device registration certificate for polyethylene embolization microspheres [13] - Fosun Pharma's subsidiary's drug registration application was accepted by the National Medical Products Administration [13] - Xianhui Technology signed contracts worth 796 million yuan with multiple subsidiaries of CATL [15] Group 6 - Ningbo Fangzheng signed a strategic cooperation agreement with Huaxiang Qiyuan for the development of various robotic technologies [15] - Ruida Futures' vice president resigned for personal reasons [16] - Samsung Medical is expected to win contracts worth approximately 125 million yuan from the State Grid [17] Group 7 - Tianjin Pharmaceutical's injectable methylprednisolone sodium succinate received registration from Panama's Ministry of Health [19] - Yaxing Anchor Chain plans to invest up to 300 million yuan in a project for deep-sea floating equipment [20] - Zejing Pharmaceutical's clinical trial for ZG006 was approved by the National Medical Products Administration [21] Group 8 - Weiye Co., Ltd. won a bid for a project worth approximately 2.086 billion yuan [23] - Ruimao Tong plans to sell 8.5794 million repurchased shares [25] - Guangge Technology's shareholders plan to reduce their holdings by up to 3.99% [26] Group 9 - Hongsheng Development signed a debt restructuring contract for a total of 2 billion yuan [27][28] - Yatai Co., Ltd. plans to reduce its holdings by up to 1% [30] - Dexin Technology's shareholder plans to reduce its holdings by up to 1% [31] Group 10 - Yaji International's shareholder plans to reduce its holdings by up to 1% [33] - Shenzhen New Star's subsidiary received approval for trial production of a boron trifluoride project [35] - Shengyi Electronics plans to raise up to 2.6 billion yuan through a private placement [36]

格隆汇11月18日丨金城医药（维权）(300233.SZ)公布，全资子公司山东金城生物药业有限公司（简 称"金城生物"）于近日收到欧洲药品质量管理局（EDQM）核准签发的谷胱甘肽原料药欧洲药典适用性 证书(简称"CEP证书"），本次金城生物获得谷胱甘肽原料药CEP证书，表明该原料药已符合欧洲药典标 准，可在欧洲市场进行销售。本次获得CEP证书有助于金城生物进一步扩展海外市场，提升公司在原料 药市场的竞争力。 ...

本次金城生物获得谷胱甘肽原料药CEP证书，表明该原料药已符合欧洲药典标准，可在欧洲市场进行销 售。本次获得CEP证书有助于金城生物进一步扩展海外市场，提升公司在原料药市场的竞争力。 金城医药(300233.SZ)发布公告，公司之全资子公司山东金城生物药业有限公司(以下简称"金城生物")于 近日收到欧洲药品质量管理局(EDQM)核准签发的谷胱甘肽原料药欧洲药典适用性证书(以下简称"CEP 证书")。 ...